Effects of syrup of Jollab on fatigue in patients with breast cancer

Study of the effect of syrup of Jollab on cancer-related fatigue in patients with breast cancer: A randomised control trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150825023753N8

Enrollment

Registered

2018-06-05

Start date

2017-11-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplastic (malignant) related fatigue. Neoplastic (malignant) related fatigue

Interventions

Intervention 1: Intervention group: patients with breast cancer-related fatigue receiving syrup of Jollab, 10 cc three times daily for four weeks

. Intervention 2: Control group: patients with breast cancer-related fatigue receiving placebo, 10 cc three times daily for four weeks.

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Female gender Age between 18- 70 years old Patients known case of breast cancer Hemoglobin level is at least 8 g / dl Hematocrit level at least 30% The level of TSH is normal

Exclusion criteria

Exclusion criteria: Patients known case of heart disease with unstable conditions Disabling Pulmonary Disease and History of Asthma Patients known case of severe kidney disease Creatinine level is greater than 2mg / dl Proteinuria The SGOT level is more than 3 times of the normal threshold Bilirubin levels is greater than 2mg / dl Positive history of hypersensitivity to saffron, Rose water and Honey Uncontrolled pain, severe infection, serious illness Positive history of gout or high level of uric acid An individual who uses antidepressants due to depression Simultaneous use of drugs that affect fatigue Unwillingness to participate in the study Active treatment for anemia (transfusion or Epoetin Alfa Injection)

Design outcomes

Primary

Measure	Time frame
Score of Fatigue Severity "Visual Analogue Fatigue Scale". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: Using Visual Analogue Fatigue Scale questionnaire.;Score of "Fatigue Severity". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: Fatigue Severity Scale questionnaire.;Score of "The Cancer Fatigue Scale". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: The Cancer Fatigue Scale questionnaire.	—

Measure

Time frame

Score of Fatigue Severity "Visual Analogue Fatigue Scale". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: Using Visual Analogue Fatigue Scale questionnaire.;Score of "Fatigue Severity". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: Fatigue Severity Scale questionnaire.;Score of "The Cancer Fatigue Scale". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: The Cancer Fatigue Scale questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghazaleh Heydarirad

Shahid Beheshti University of Medical Sciences

ghazalrad@yahoo.com+98 21 8877 6027

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026